Dr. Harlan W. Waksal, M.D., has been the Chief Executive Officer and President of Kadmon Holdings, Inc. since September 2014. Dr. Waksal has been the President and Sole Proprietor of Waksal Consulting L.L.C. since July 2003. Dr. Waksal served as an Executive Vice President of Acasti Pharma Inc. until October 2014. and previously served as its Executive Vice President of Business & Scientific Affairs since July 21, 2011. He served various positions at ImClone from 1987 to 2003. Dr. Waksal Co-founded ImClone Systems LLC in 1984 and served as its Chief Scientific Officer since April 29, 2003. From March 1987 to April 1994, Dr. Waksal served as the President at the firm. From March 1987 to May 2002, he served as the Chief Operating Officer and Executive Vice President at ImClone Systems Corporation and also served as its Chief Executive Officer from May 2002 to July 2003. Dr. Waksal was instrumental in guiding the development and obtaining FDA approval for a new targeted biologic cancer therapy known as Erbitux. From 1984 to 1985, he served as the Chief Resident in Pathology at Kings County Hospital. He served as the Chairman of Sevion Therapeutics, Inc. (alternate name Senesco Technologies Inc) since June 8, 2009 until March 2016 and served as its Director since October 2008 until March 2016. He has been a Director at Kadmon Holdings, Inc. since 2013. Dr. Waksal serves as a Member of the Advisory Board of Roadmap Capital Inc. He serves on the Technology Advisory Board for New Jersey Edison Innovation Fund. Dr. Waksal served as a Director of Acasti Pharma Inc. since June 28, 2013 until February 29, 2016. He served as a Director of ImClone Systems LLC from April 1984 to January 2005. He served as a Director of Neptune Technologies & Bioresources, Inc. from May 23, 2012 to July 14, 2015. Dr. Waksal served as a Director at NeuroBiopharm Inc. He serves on the Board of Directors of Oberlin College and is a Member of the Board of Trustees of The Montclair Art Museum. Dr. Waksal is an Adjunct Assistant Professor in the Department of Pathology at Downstate Medical Center, New York. He is involved in the execution of the strategic development plan, especially in the clinical development program. He is also involved in other scientific operations as well as in business development. Dr. Waksal is the Inventor of multiple patents and patent applications. He is a Physician. He is the author of 50 published scientific papers, many in the area of oncology. Dr. Waksal has over 30 years of executive and governance leadership in the life sciences. Dr. Waksal received his training in Internal Medicine from Tufts-New England Medical Center Hospital and in Pathology from Kings County Hospital in Brooklyn, New York from 1982 to 1987. He received a Bachelor of Arts in Biology from Oberlin College in 1975. Dr. Waksal received his Medical Degree from Tufts University School of Medicine in 1979. Dr. Harlan W. Waksal, M.D., has been the Chief Executive Officer and President of Kadmon Holdings, Inc. since September 2014. Dr. Waksal has been the President and Sole Proprietor of Waksal Consulting L.L.C. since July 2003. Dr. Waksal served as an Executive Vice President of Acasti Pharma Inc. until October 2014. and previously served as its Executive Vice President of Business & Scientific Affairs since July 21, 2011. He served various positions at ImClone from 1987 to 2003. Dr. Waksal Co-founded ImClone Systems LLC in 1984 and served as its Chief Scientific Officer since April 29, 2003. From March 1987 to April 1994, Dr. Waksal served as the President at the firm. From March 1987 to May 2002, he served as the Chief Operating Officer and Executive Vice President at ImClone Systems Corporation and also served as its Chief Executive Officer from May 2002 to July 2003. Dr. Waksal was instrumental in guiding the development and obtaining FDA approval for a new targeted biologic cancer therapy known as Erbitux. From 1984 to 1985, he served as the Chief Resident in Pathology at Kings County Hospital. He served as the Chairman of Sevion Therapeutics, Inc. (alternate name Senesco Technologies Inc) since June 8, 2009 until March 2016 and served as its Director since October 2008 until March 2016. He has been a Director at Kadmon Holdings, Inc. since 2013. Dr. Waksal serves as a Member of the Advisory Board of Roadmap Capital Inc. He serves on the Technology Advisory Board for New Jersey Edison Innovation Fund. Dr. Waksal served as a Director of Acasti Pharma Inc. since June 28, 2013 until February 29, 2016. He served as a Director of ImClone Systems LLC from April 1984 to January 2005. He served as a Director of Neptune Technologies & Bioresources, Inc. from May 23, 2012 to July 14, 2015. Dr. Waksal served as a Director at NeuroBiopharm Inc. He serves on the Board of Directors of Oberlin College and is a Member of the Board of Trustees of The Montclair Art Museum. Dr. Waksal is an Adjunct Assistant Professor in the Department of Pathology at Downstate Medical Center, New York. He is involved in the execution of the strategic development plan, especially in the clinical development program. He is also involved in other scientific operations as well as in business development. Dr. Waksal is the Inventor of multiple patents and patent applications. He is a Physician. He is the author of 50 published scientific papers, many in the area of oncology. Dr. Waksal has over 30 years of executive and governance leadership in the life sciences. Dr. Waksal received his training in Internal Medicine from Tufts-New England Medical Center Hospital and in Pathology from Kings County Hospital in Brooklyn, New York from 1982 to 1987. He received a Bachelor of Arts in Biology from Oberlin College in 1975. Dr. Waksal received his Medical Degree from Tufts University School of Medicine in 1979.

Immunobiology